Eli Lilly and Company

Ligand Pharmaceuticals, Inc.

Kevin Matthew Gardinier

Albert Kudzovi Amegadzie

Erik James Hembre, Ii

Kenneth Allen Savin

David Joseph Garmene

Louis Nickolaus Jungheim

James Peter Beck

Jianliang Lu

Patrick Gianpietro Spinazze

Winton Dennis Jones, Jr

Daryl Lynn Smith

Steven James Green

Jennifer Rebecca Allen

Douglas Linn Gernert

Michael Alan Robertson

Jian Eric Hong

George Stuart Gregory

Paul J Hoogestraat

Yen Dao

Brian David Wakefield

Marcus F Boehm

Paul Leslie Ornstein

Stephen A Hitchcock

Jon Kevin Reel

Brian Stephen Muehl

Warren Jaye Porter

Timothy A Grese

Pierre-Yves Michellys

David Andrew Neel

Macklin Brian Arnold

Daniel Ray Mayhugh

David Michael Remick

Sean Patrick Hollinshead

Freddie Craig Stevens

Jeffrey Michael Schkeryantz

Helen Jane Szekeres

Patric James Hahn

Albert Khilevich

Esteban Dominguez-Manzanares

Michael Brunavs

Christopher M Mapes

Frederic Laurent Cordier

Steven Andrew Hitchcock

Peter Michael Greenen

James Craig Ruble

Jeffrey Michael Witkin

Erik James Hembre

Winton Dennis Junior Jones

A TARP &#x3b3;8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N;A is andRis as defined herein;its pharmaceutically acceptable salts, uses, and methods for its preparation are described.

[object Object]

The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R, R, R, R, L, R, Rand Rare as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases. 

MCH receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R, R, R, R, L, R, Rand Rare as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases. 

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein '-----' is absent or is optionally a bond; q is 1 or 2; Ris independently selected from hydrogen, &#x2014;C-Calkyl, halo, hydroxy, &#x2014;C-Chaloalkyl, &#x2014;C-Calkoxy, cyano, &#x2014;O&#x2014;C-Ccycloalkyl, and &#x2014;OC-Chaloalkyl; Ris selected from the group consisting of hydrogen, &#x2014;C-Calkyl, hydroxy, &#x2014;C-Calkoxy, cyano, &#x2014;C-Chaloalkyl, &#x2014;OC-Chaloalkyl, and halo; Ris selected from the group consisting of hydrogen, &#x2014;C-Calkyl, &#x2014;C-Chaloalkyl, &#x2014;C-CalkylOH, &#x2014;C-Ccycloalkyl, &#x2014;CHC-Ccycloalkyl, &#x2014;C-Calkyl-O&#x2014;C-Calkyl, &#x2014;C(O)C-Calkyl, &#x2014;C(O)C-Chaloalkyl, &#x2014;CH-thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C-Calkyl, and &#x2014;C-Chaloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases. 

5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R, q, p, R, t, Ar, L, Rand Rare as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases. 

Thiazolopyridinone derivates as MCH receptor antagonists

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar, L, R, q, X, R, R, R, and Rare as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. 

CB1 modulator compounds

The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

Retinoid X receptor modulators

This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C-Calkane-diyl; Ris phenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C-Calkyl, C-Calkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; Ris a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH) 

Triazole derivatives as tachykinin receptor antagonists

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith 

CB1 antagonist compounds

The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins 

Tachykinin receptor antagonists

Growing community of inventors

Fishers, IN, United States of America

Kevin Matthew Gardinier